PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12714868-7	2003	The ERK1/2 kinase cascade inhibitor PD 98059 significantly impaired the expression of nNOS in arteries exposed to 200 mmHg for 9 h. However, the angiotensin AT(1) antagonist candesartan and the angiotensin converting enzyme inhibitor perindoprilat did not have any effect under the same experimental conditions.	candesartan	174-185	mitogen activated protein kinase 3	Rattus norvegicus	4-10	
14871417-12	2004	Furthermore, candesartan decreased renal tissue Ang II contents (from 216 +/- 19 to 46 +/- 3 fmol/mL) and ERK1/2, JNK, and BMK1 activities (-45%, -60%, and -70%, respectively) in DS/H rats.	candesartan	13-24	mitogen activated protein kinase 3	Rattus norvegicus	106-112	
19948989-13	2010	Extracellular signal-regulated kinase 1/2 activation in high-flow arteries was prevented by perindopril and candesartan and not by hydralazine.	candesartan	108-119	mitogen activated protein kinase 3	Rattus norvegicus	0-39	
11941388-8	2000	(2) After pretreatment with PD098059 or CV11974, AngII-induced increases in p44MAPK and p42MAPK protein expression and enzyme activity (expressed by gamma-(32)P-ATP incorporation) were all inhibited obviously.	candesartan	40-47	mitogen activated protein kinase 3	Rattus norvegicus	76-83	
34803077-10	2022	Moreover, 1 muM SCH772984 (a selective inhibitor of extracellular signal-regulated kinase, ERK1/2) and 500 muM SQ22536 (a cell-permeable adenylate cyclase (AC) inhibitor) markedly abolished neuroprotective effects of candesartan and enalapril.	candesartan	217-228	mitogen activated protein kinase 3	Rattus norvegicus	91-97	
34803077-11	2022	These results indicate that RAASIs possess preventive or therapeutic effects in acute and chronic OIPN, candesartan and enalapril may directly increase in the activity of ERK1/2 and AC in PC12 cells.	candesartan	104-115	mitogen activated protein kinase 3	Rattus norvegicus	171-177	
20927110-7	2010	AngII-induced ERK 1/2 phosphorylation and cell proliferation in SHR were inhibited by pretreatment with an AT1 receptor blocker, candesartan and an inhibitor of MEK, PD98059.	candesartan	129-140	mitogen activated protein kinase 3	Rattus norvegicus	14-21	
20535114-11	2010	ERK1/2 activation (ratio phospho-ERK/ERK) was higher in LF arteries, and this activation was prevented by perindopril and candesartan.	candesartan	122-133	mitogen activated protein kinase 3	Rattus norvegicus	0-6	
28095237-9	2001	ET-1-induced activation of ERKs, SAPKs and p38 was also partially, but significantly, reduced by candesartan.	candesartan	97-108	mitogen activated protein kinase 3	Rattus norvegicus	27-31	
11040245-8	2000	Ang II type 1 receptor blockade by candesartan (10 micromol/L) abolished the Ang II-induced increase in ERK1/2 activity, but Ang II type 2 receptor blockade (PD123319, 10 micromol/L) did not.	candesartan	35-46	mitogen activated protein kinase 3	Rattus norvegicus	104-110	
34428599-8	2021	However, the levels of phosphorylated Cx43 decreased after pre-treatment with candesartan (AT1 receptor blocker), GF109203X (protein kinase C (PKC) blocker) and U0126 (mitogen-activated protein kinases/extracellular signal-regulated kinase1/2(MEK/ERK1/2)-specific blocker) in AngII-stimulated A7r5 cells.	candesartan	78-89	mitogen activated protein kinase 3	Rattus norvegicus	247-253